A multimorphic variant in ThPOK causes a novel human disease characterized by T cell abnormalities, immunodysregulation, allergy, and fibrosis

Maryam Vaseghi-Shanjani^{1,2*}, Mehul Sharma^{2*}, Pariya Yousefi², Simran Samra¹,² Kaitlin U. Laverty³, Arttu Jolma³, Rozita Razavi³, Ally H. W. Yang³, Mihai Albu³, Liam Golding², Anna F. Lee⁴, Ryan Tan², Phillip A. Richmond⁵, Marita Bosticardo⁶, Jonathan H. Rayment², Connie L. Yang², Kyla J. Hildebrand², Rae Brager⁷, Michelle K. Demos², Yu Lung Lau⁸, Luigi D. Notarangelo⁶, Timothy R. Hughes⁹, Catherine M. Biggs^{2†}, Stuart E. Turvey^{2†}

¹Experimental Medicine Program, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
²Department of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.
³Donnelly Centre, University of Toronto, Toronto, ON, Canada.
⁴Department of Pathology and Laboratory Medicine, BC Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.
⁵The Rare Disease Discovery Hub, BC Children's Hospital Research Institute, The University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada.
⁶Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
⁷Division of Rheumatology, Immunology, and Allergy, Department of Paediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
⁸Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, China.

⁹Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

*Denotes equal contribution as co-first authors †Denotes equal contribution as co-senior authors

Correspondence to:

Stuart E. Turvey, MBBS, DPhil, FRCPC BC Children's Hospital 950 West 28th Avenue Vancouver, BC, V5Z 4H4, Canada Email: sturvey@bcchr.ca

Abstract

ThPOK is best known as a regulator of CD4+ T cell lineage commitment, although it was initially cloned as a suppressor of collagen expression in the skin. The role of ThPOK has not been formally established in humans since individuals with damaging variants in ThPOK have not yet been identified. Here, we report the first case of a human with a damaging heterozygous de novo variant in ThPOK causing a syndrome encompassing CD4+ T cell deficiency, allergy, fibroinflammatory interstitial lung disease, developmental delay, and growth failure. The patient's variant, ThPOK^{K360N}, exhibited abnormal multimorphic activity, including interfering with ThPOK^{WT} in regulating gene regulation (antimorph). Protein-DNA interaction assays showed inability of ThPOK^{K360N} to bind to wild-type consensus sequences (amorph) and revealed a novel DNAbinding specificity (neomorph). Single-cell RNA sequencing of peripheral blood revealed potential developmental defects in maturation and activation of CD4+ and CD8+ T cells (hypomorph). To establish causality, we recapitulated the observed cellular defects in lentivirally transduced healthy control T cells and pulmonary fibroblasts. Transcriptomic analysis showed that T cells transduced with ThPOK^{K360N} lacked the upregulation of activation, proliferation, and functional pathways observed in ThPOK^{WT}-transduced cells. When overexpressed in healthy control fibroblasts, ThPOKK360N significantly increased the expression of pro-fibrotic genes implicated in pulmonary fibrosis, indicating a defect in regulating collagen expression. This novel human disease caused by a multimorphic variant in ThPOK confirms its role in CD4+ T cell development in an intact human context, while also revealing an unanticipated role for ThPOK in T cell function and the regulation of fibrotic pathways in fibroblasts.

One sentence summary: Discovery of a human with pathogenic multimorphic genetic change in ThPOK establishes ThPOK as essential for human T cell development and reveals its novel role as a regulator of fibrosis.

1 INTRODUCTION

2 T-helper-inducing POZ/Kruppel-like factor (ThPOK), encoded by ZBTB7B, is a transcription 3 factor that belongs to the zinc finger and BTB/POZ domain-containing (ZBTB) family of proteins 4 (1). ThPOK acts both as an activator and a suppressor of transcription through direct binding to 5 promoter regions of target genes and by interaction with various co-regulators (2). In recent years, 6 ThPOK has garnered significant attention in immunological research, primarily through insights 7 gained from murine models. The most well-studied function of ThPOK is its role in directing the 8 differentiation of T cell lineages, particularly in promoting the development of CD4+ T cells and 9 inhibiting the development of CD8+ T cells in the thymus (3). This discovery was initially made 10 based on a spontaneous mutant mouse strain with biallelic missense variants in the second zinc 11 finger domain of ThPOK. These so-called 'helper-deficient' (HD) mice show a selective absence 12 of mature CD4+ T cells and increased frequency of CD8+ T cells. While the primary focus on 13 ThPOK has been its immune functions, its role extends to other biological processes, although 14 these are less well-understood. For example, ThPOK is highly expressed in the skin and 15 downregulates type I collagen gene expression in murine skin fibroblasts, binding specifically to 16 the regulatory regions of type I collagen genes (Collal and Colla2) (4).

Despite advances in our understanding of the role of ThPOK in immunity, the direct implications of *ZBTB7B* variants in human health have remained largely unexplored. To date, disabling genetic changes in ThPOK have not been implicated as a cause of human monogenic disease. Here, we describe a patient with a *de novo* heterozygous pathogenic variant in *ZBTB7B* causing a complex syndromic phenotype including CD4+ T lymphopenia, CD8+ T lymphocytosis, early-onset allergic disease, severe fibroinflammatory interstitial lung disease, and failure to thrive. Our detailed mechanistic investigations reveal that this variant is multimorphic, exhibiting

antimorphic dominant-negative (DN), amorphic and hypomorphic loss-of-function (LOF), and 24 25 neomorphic gain-of-function (GOF) effects. Our findings, in the context of the whole human 26 organism, both reinforce the well-established role of ThPOK in T cell development, as 27 demonstrated by the patient's abnormalities in T cell development and function, but also emphasize 28 the unexpected role of ThPOK in pulmonary fibrosis, as demonstrated by the increase in pro-29 fibrotic gene signature in fibroblasts expressing the variant. These findings not only elucidate and 30 challenge the current understanding of ThPOK's role in the immune system, but also open new 31 avenues for exploring its broader implications in other tissues and body systems in humans.

32 **RESULTS**

33

34 A novel *de novo* heterozygous *ZBTB7B* variant in a child with immunodeficiency, allergic

35 disease, and interstitial lung disease

36 The patient is young male child born to healthy non-consanguineous parents. His complex clinical 37 course was notable for global developmental delay, failure to thrive (Figure S1), bilateral 38 sensorineural hearing loss (Figure S2), non-healing corneal ulceration, increased echogenicity of 39 multiple tissues (i.e. pancreas, liver and kidneys), growth hormone deficiency, allergic disease, 40 combined immunodeficiency, and severe interstitial lung disease requiring supplemental oxygen 41 (Figure 1A). He had persistent chest imaging abnormalities (Figure 1B-C) and lung biopsy 42 demonstrated chronic inflammation and fibrosis of the lung, characterized by lipoproteinosis and 43 notable subpleural cystic remodeling and honeycomb changes (Figure 1D-I).

Although T cell receptor excision circle (TREC) counts were normal at birth, CD4+ lymphopenia was identified in infancy. Detailed immunophenotyping showed CD4+ lymphopenia and reduced naïve CD4+ T cell percentage, with the opposite finding in CD8+ T cells of lymphocytosis and elevated naïve percentage, and B cell lymphocytosis (Table S1).

Due to this unusual constellation of issues, trio whole-genome sequencing was pursued which identified a novel heterozygous *de novo* variant in *ZBTB7B* (NM_001256455.2:c.1080A>C, p.K360N), predicted to be damaging using *in silico* prediction tools (Table S2). The sequencing results were validated by Sanger sequencing in all family members (Figure 1J-L). The variant results in a substitution from a positively charged lysine residue to a polar uncharged asparagine residue at a highly conserved region of the protein (Figure S3), altering the first zinc finger in the DNA-binding domain of ThPOK (Figure 1J).

55

56 **ThPOK**^{K360N} displays altered neomorphic DNA binding specificity

We assessed the effect of the NM_001256455.2:c.1080A>C (p.K360N) variant on protein expression using HEK293 cells. We selected HEK293 cells as our model system as these cells lack endogenous expression of ThPOK (www.proteinatlas.org/). Expression of ThPOK^{K360N} was assessed both in isolation and in combination with ThPOK^{WT}, modelling the patient's heterozygous state. Expression of ThPOK^{K360N} remained comparable to ThPOK^{WT} both in isolation and in the heterozygous state, suggesting that the presence of the variant does not impact protein expression (Figure 2A, Figure S4).

64 Next, we evaluated the effect of the variant on the function of ThPOK as a transcription 65 factor and its regulatory influence on SOCS1 expression. Building on Luckey et al.'s identification 66 of ThPOK-binding sites within the mouse *Socs1* promoter region (5), we developed a luciferase 67 reporter assay utilizing a segment of the human SOCS1 promoter containing the previously identified DNA binding motif of ThPOK (6). We established that ThPOK^{K360N} is impaired in its 68 ability to upregulate SOCS1 transcriptional activity compared to ThPOKWT (Figure 2B). When co-69 70 transfecting cells to mimic the heterozygous state with both wild-type (WT) and p.K360N ZBTB7B 71 plasmids, the transcriptional activity of SOCS1 exhibited an intermediate increase (Figure 2B). We 72 then investigated the potential dominant-negative effect of ThPOK^{K360N} on ThPOK^{WT} by 73 systematically increasing the ratio of the variant plasmid relative to the WT plasmid. Here we 74 observed an inverse relationship between the amount of the variant plasmid and SOCS1 transcriptional activity (Pearson correlation: $r^2 = 0.9262$, p-value = 0.0005) (Figure 2C). 75

To further assess the DNA-binding ability of ThPOK^{K360N}, we employed an electrophoretic
 mobility shift assay (EMSA) using a tagged 35 nucleotide probe from the *SOCS1* promoter. We

observed that ThPOK^{WT} could effectively bind to this probe, while ThPOK^{K360N} could not (Figure S5). To ensure the observed binding was specific, a supershift assay was performed and confirmed that the ThPOK variant exhibited no detectable binding activity, indicating a loss of DNA-binding capability likely attributable to the missense change in the DNA-binding zinc finger (Figure 2D). Additionally, a competition assay with a 100-fold excess of unlabeled competitor probe substantially diminished the supershifted ThPOK^{WT}-DNA complex band, further verifying the specificity of the binding (Figure 2E).

85 We used structural modeling to evaluate the predicted impact of the amino acid change at 86 position 360 on the ability of ThPOK to interact with DNA, using the paralog ZBTB7A 87 (PDB:8E3D), which shares sequence homology in the DNA-binding zinc finger domain with 88 ThPOK (7). The structural analysis of ZBTB7A bound to a DNA target revealed that the lysine 89 residue, equivalent to the changed 360 site in ThPOK, forms direct hydrogen bonds with the bases 90 of AG dinucleotide. Consequently, the variant in ThPOK likely disrupts these interactions, altering 91 its DNA binding specificity (Figure S6). To experimentally define and compare the DNA binding 92 profiles of ThPOK^{WT} and ThPOK^{K360N}, we utilized high-throughput systematic evolution of 93 ligands by exponential enrichment (HT-SELEX). The HT-SELEX results further corroborated changes in DNA binding specificity of ThPOK^{K360N} compared to ThPOK^{WT} (Figure 2F). Position 94 95 weight matrices (PWM) revealed a shift in nucleotide preference in positions 3 and 4, specifically 96 changing 'GA' nucleotides, preferred by the WT, to 'CT' or 'AT' nucleotides, preferred by ThPOK^{K360N}. Notably, both 'C' and 'A' were similarly preferred at position 3 for ThPOK^{K360N} 97 98 (Figure 2F). Additionally, the relative abundance of 8-mer sequences from HT-SELEX experiments revealed that sequences with high affinity for either ThPOK^{WT} or ThPOK^{K360N} 99

100 generally had a low incidence in the counterpart's selection. This distinct separation underscores the divergent DNA binding specificities between ThPOK^{WT} and ThPOK^{K360N} (Figure 2G). 101 102 Given that the original 'GA' dinucleotide at positions 3 and 4 in the WT binding sequence 103 is highly conserved and exhibits low flexibility, changes to this sequence are likely to impact 104 binding specificity. To test this using EMSA, we created two variant oligonucleotide probes 105 informed by the highest hit of the 8-mer plot (Variant Probe 1) and the consensus sequence for 106 ThPOK^{K360N} as indicated by PMW obtained from HT-SELEX (Variant Probe 2) that incorporated 107 the dinucleotide modifications 'AT' (3'...CATCCCCC...5') or 'CT' (3'...CCTCCACC...5') 108 respectively (see Table S3 for full-length probe sequences). Our results demonstrated that 109 ThPOK^{K360N} exhibited strong binding affinity to Variant Probe 1 and 2 (Figure 2H). 110 To further assess the DNA binding landscape of the transcription factor, we integrated the

111 HT-SELEX motifs with corresponding chromatin immunoprecipitation followed by sequencing (ChIP-seq) data to identify high-confidence gene targets for both ThPOK^{WT} and ThPOK^{K360N}. A 112 113 gene was designated as a high-confidence target based on the co-occurrence of ChIP-seq peaks in 114 all replicates within the promoter regions (spanning from -1000 to +500 bp relative to the 115 transcription start site) that also harbored corresponding HT-SELEX motif hits (Figure 2I). Our analysis revealed distinct gene targets likely to be regulated by ThPOK^{WT} and ThPOK^{K360N}, as 116 117 illustrated by the Venn diagram (Figure 2I), with limited overlap between the gene sets and associated pathways (data file S1) targeted by each protein, suggesting that ThPOKWT and 118 119 ThPOK^{K360N} engage in differential regulatory networks. This pattern indicates potentially unique 120 transcriptional roles for each protein, which may underlie differences in cellular responses and 121 phenotypic outcomes.

122

123 Patient T cells have impaired development, memory phenotype skewing, and enhanced Th2

124 effector function

125 ThPOK plays a critical role in the development of lymphoid cells, particularly in the lineage commitment of CD4+ T cells (1-3, 5, 8) (Figure 3A). To define how ThPOKK360N impacts T cell 126 127 development, we first performed immunophenotyping of the patient's lymphoid compartment. 128 Clinical flow cytometry data, collected over multiple time points, consistently revealed T cell 129 abnormalities; notably persistent CD4+ lymphopenia, CD8+ lymphocytosis, and a lower 130 CD4+/CD8+ ratio, all while largely maintaining a normal absolute CD3+ count in comparison to 131 age-matched controls (Figure 3B). Clinical lymphocyte studies also indicated significant 132 abnormalities in T cell naïve and memory subpopulations. The patient has persistently low 133 proportion of CD4+ naive T cells and high proportion of CD4+ central memory and effector 134 memory T cells. Additionally, the CD8+ T cell compartment shows an unusually high proportion 135 of naive T cells, while the percentages of CD8+ central memory, effector memory, and TEMRA 136 T cells are consistently low. This pattern underscores a persistent imbalance in the patient's T cell 137 maturation and memory formation processes. Memory B cells also showed a skewed distribution, 138 with low levels of switched, unswitched memory and transitional B cells and high levels of naive 139 B cells (Table S1).

Along with the clinical observation of severe atopic manifestations in the patient, we also observed transient peripheral blood eosinophilia in the first 2 years of life and persistently elevated serum IgE levels (Figure 3C). This prompted an examination of the T helper 2 (Th2) cell in patient primary cells. We conducted an immunophenotyping study using flow cytometry to analyze the T cell compartment using blood drawn from the patient at three different points over two years. For comparative analysis, we included three age-matched pediatric healthy controls (HC) and four

146 adult HCs. We first confirmed reduction in frequency of total CD4+ T cells and increase in CD8+ 147 proportion in the CD3 compartment (Figure 3D). Within the CD4+ T cell population, there was an increase in the frequency of memory T cells alongside a substantial decrease in naive CD4+ T cells 148 149 in the patient, in line with the clinically collected data (Figure 3E). Upon stimulation with PMA 150 and ionomycin, a marked increase in Th2 cell activity was observed in the patient. This was 151 characterized by elevated production of Th2 effector cytokines, including IL-4, IL-5, and IL-13 152 (Figure 3F-G). These findings suggest that the patient exhibits distinct immune dysregulation, 153 particularly in the T cell compartment, with a pronounced shift towards memory phenotypes and 154 Th2 effector function.

155

156 Patient T cells exhibit impaired differentiation and activation

157 To understand the molecular underpinnings of the observed developmental T cell defect, we 158 conducted single-cell RNA sequencing combined with antibody sequencing (scRNA-seq/Ab-seq) 159 on the peripheral blood mononuclear cells (PBMCs) of the patient and two HCs, with and without 160 T cell receptor (TCR) stimulation. Dimensionality reduction using UMAP on the unstimulated 161 global transcriptomic signature did not place the patient's T cells, NK cells, B cells or monocytes 162 in a separate cluster from those of the HCs (Figure 4A). Quantitative assessment of T cell subset 163 proportions, as measured using surface marker sequencing, did confirm clinical flow cytometry 164 data: the patient exhibited low CD4+ T cells and high CD8+ T cells (Figure 4B). However, T cells 165 specific clustering, visualized with UMAP, revealed that the patient's T cells cluster separately 166 from HC T cells. This difference in clustering was independent of CD4+, CD8+ or naïve and 167 memory (using CD45RO) subset classification as determined by cell surface staining (Figure 4C). 168 Patient T cells were largely naïve CD8+ but did not cluster with naïve T cells of HCs (Figure 4C).

169 Given the stark differences in transcriptomic signatures of patient T cells, we studied each 170 of the key T cell subpopulations. Leveraging the BD® AbSeq Antibody-Oligonucleotides 171 Conjugates, we were able to identify CD4+ and CD8+ expressing T cells in our scRNA-seq data. 172 We examined double positive (DP) T cells, as they could reflect potential developmental defects 173 in the final stages of T cell maturation in the thymus. We noted that the lineage commitment gene 174 TCF3 was upregulated in the patient's DP T cells compared to HCs (Figure 4D). The accumulation 175 of TCF3 could suggest a defect in the downstream mediators of CD4+ T cell commitment, namely 176 ThPOK and GATA3 (9-11). Subsequently, we investigated gene signatures in naïve CD4+ and 177 CD8+ T cells. While we did not see differences between patient and HCs at baseline, we did see 178 differences after TCR stimulation. Here, strong skewing was observed in both the naïve CD4+ and 179 CD8+ compartment of patient T cells suggestive of impaired TCR activation compared to HCs 180 (Figure 4E-H). A lack of T cell activation was particularly evident with patient cells failing to 181 upregulate proliferative signaling pathways in CD4+ T cells (e.g., the MYC pathway) and effector 182 CD8+ T cell pathways (e.g., interferon pathways) (Figure 4F and 4H). These results suggest a 183 significant role for ThPOK in the activation of matured single-positive T cells. To establish this 184 link experimentally, we stably transduced T cells with EV, WT, or p.K360N ThPOK containing 185 lentiviral plasmids, and cultured them for 3 days. We observed that many pathways (e.g., MYC 186 proliferation, and interferon effector) were upregulated in WT-transduced T cells, but these 187 pathways failed to upregulate in p.K360N-transduced cells (Figure 3I). These results showed that 188 the defects in T cell activation were attributable to the dominant-interfering effect of ThPOK^{K360N}. 189

190 **ThPOK**^{K360N} disrupts profibrotic gene suppression in pulmonary fibroblasts

In addition to the T cell defects, the patient carrying ThPOK^{K360N} had evidence of multi-organ 191 192 fibrosis, and it has previously been shown that murine ThPOK binds to the regulatory regions of 193 collagen genes in the skin to inhibit their expression (4). Using HEK293 cells, which express 194 COL2A1 but lack endogenous expression of ThPOK, we compared the effects of transduced ThPOK^{K360N} to ThPOK^{WT}. Our results show that while ThPOK^{WT} suppresses *COL2A1* expression 195 196 as expected, ThPOK^{K360N} does not, leading to significantly higher COL2A1 levels similar to the control with an EV (Figure 5A). Additionally, cells expressing both ThPOK^{WT} and ThPOK^{K360N}, 197 198 mimicking a heterozygous state, also showed significantly increased COL2A1 expression compared to ThPOK^{WT} alone (Figure 5A), indicating a dominant interfering effect of ThPOK^{K360N} 199 200 on ThPOK^{WT} in repressing collagen expression. This led us to further validate our findings through 201 stable lentiviral transduction, highlighting ThPOK's critical role in regulating collagen gene 202 expression. Since ThPOK is highly expressed in fibroblasts (www.proteinatlas.org/) and acts as a 203 repressor of murine Collal and Colla2 (also highly expressed in fibroblasts) (4), we utilized 204 primary human pulmonary fibroblasts as a model system. HC pulmonary fibroblasts were stably 205 transduced with either EV, WT, or p.K360N ThPOK containing lentiviral plasmids (Figure 5B). 206 Principal component analysis (PCA) of bulk RNA sequencing data showed clear and distinct 207 clustering for each group. Principal Component 1 (PC1) and PC2 accounted for 52.6% and 32.9% 208 of the total variance, respectively, and highlighted large differences in gene expression profiles 209 influenced by ThPOK status (Figure 5C). Differential analysis between EV-transduced and WT 210 ThPOK-transduced fibroblasts showed significant gene expression changes, many of which are 211 not observed to the same level in variant-transduced cells (Figure 5D). Interestingly, overexpression of ThPOK^{K360N} led to altered gene expression profiles compared to ThPOK^{WT}, 212 213 with a number of genes that were upregulated in the WT being downregulated in the variant and

vice versa (Figure 5D and 5E). This shift indicates that the missense change in the first zinc finger of ThPOK significantly changes its regulatory impact, potentially altering its DNA-binding affinity, interaction with other proteins, or responsiveness to cellular signals.

217 Pathway analysis of the transcriptomic data revealed downregulation of critical pathways 218 including interferon alpha and gamma signaling, as well as the inflammatory response pathway in 219 the variant-transduced cells compared to WT-transduced controls. Conversely, upregulation was 220 observed in several pathways, such as estrogen response late, Myc targets, and epithelial 221 mesenchymal transition (Figure 5F). The upregulation of the epithelial mesenchymal transition, a 222 pathway integral to fibrosis and wound healing, was notable as it underlined the variant's role in 223 potentially exacerbating fibrotic conditions, highlighting a key area for further investigation. This 224 is supported by the differential expression of several pro-fibrotic genes –ACTA2 (12-20), TGFB1 225 (18, 21, 22), LTBP2 (19, 23, 24), and BDNF (25), and COL1A1 (20, 26), and MDK (27)- that 226 have been implicated in pulmonary fibrosis by multiple studies (Figure 5G). These genes have 227 significantly increased transcript abundance in fibroblasts stably expressing ThPOKK360N to 228 compared to WT controls. These findings suggest that ThPOK^{K360N} represents a LOF in its ability 229 to suppress fibrosis and profibrotic gene expression in fibroblasts, thereby highlighting the crucial 230 role of ThPOK in maintaining cellular homeostasis against fibrotic processes.

231

Reversal of fibrotic gene signature in patient pulmonary fibroblasts is achieved by overexpression of WT ThPOK or pirfenidone treatment

We next utilized patient-derived primary pulmonary fibroblasts to determine if stable overexpression of ThPOK^{WT} could reverse the observed fibrotic gene signature (Figure 5H). Our results revealed that the previously identified profibrotic genes in the transduced HC pulmonary

fibroblasts exhibited similar differential regulation patterns in transduced patient-derived cells.
Notably, there was a decrease in transcript abundance of the profibrotic genes in the patientderived fibroblasts stably expressing the WT gene, thereby indicating a successful rescue of the
patient-derived cells from the fibrotic phenotype (Figure 5I).

241 Building on our previous findings, we tested the efficacy of Food and Drug Administration 242 (FDA)-approved pulmonary fibrosis drugs – pirfenidone (28-30) and nintedanib (29-31) – on 243 patient-derived pulmonary fibroblasts in their steady state, and also under fibrosis-induced 244 conditions. This approach was designed to better mimic the fibrotic microenvironment of the 245 patient's lungs, acknowledging that in vivo, cells are influenced by surrounding signals and are not 246 isolated. For the induction of a fibrotic cell model, we employed transforming growth factor beta 247 $(TGF-\beta)$ stimulation, a method well-established in the literature for simulating a fibrosis response 248 in human fibroblasts (20, 30). We used ACTA2 expression via qPCR as our primary readout, due 249 its recognition in the literature as a critical marker of myofibroblasts and activated fibroblasts, key 250 players in fibrotic disease progression across various organs, including the lungs (12-20). Optimal 251 in vitro treatment doses were determined by conducting dose-response experiments and assessing 252 cytotoxicity in our model system using the lactate dehydrogenate (LDH) release cytotoxicity assay 253 (Figure S7). We demonstrated that treatment with pirfenidone (1mM) over a 48-hour period 254 reduced ACTA2 expression in TGF- β -treated fibroblasts in comparison to untreated controls 255 (Figure 5J). In contrast, a similar 48-hour treatment regimen with nintedanib (0.1µM) did not 256 produce a comparable effect (Figure 5J). This finding highlights the efficacy of pirfenidone in 257 modulating the fibrotic gene signature and may underscore the drugs' distinct mechanisms of 258 action and their varied impact on fibrotic pathways in patient-derived pulmonary fibroblasts.

259 **DISCUSSION**

260 We describe the first reported human with a monogenic disorder caused by disruption of ZBTB7B 261 which encodes the transcription factor ThPOK. This patient who was heterozygous for a variant 262 in ZBTB7B presented with a complex syndromic phenotype including combined 263 immunodeficiency, severe atopy, severe fibroinflammatory interstitial lung disease, sensorineural 264 hearing loss, global developmental delay, and growth failure. Our investigations align with the 265 established guidelines for genetic studies in single patients, as proposed by Jean-Laurent Casanova 266 (32): the identified variant is not found in the unaffected parents or sibling; the variant is rare and 267 absent in the gnomAD population database; in silico tools predict the variant to be damaging; and 268 our functional investigations indicate that ThPOK^{K360N} exhibits multimorphic damaging effects.

269 The discovery of a monogenic defect in ThPOK in our patient has offered an exciting 270 opportunity to explore the role of ThPOK in human immunology, providing a direct *in vivo* context 271 that was previously inaccessible and primarily inferred from the HD mice and in vitro human 272 studies. ThPOK is best known for its role as a 'master regulator' of CD4+ lineage commitment in 273 the thymus, where it has been shown to be crucial for CD4+ versus CD8+ lineage decisions, 274 particularly in MHC-II-restricted CD69+ CD4+ CD8^{low} intermediate thymocytes (1-3, 8, 33-37). 275 This was first discovered through the HD mouse model characterized by the selective absence of 276 mature CD4+ T cells in the periphery and increased numbers of CD8+ cells (38). Our observations 277 of persistent CD4+ lymphopenia and CD8+ lymphocytosis in the patient's T cell compartment 278 recapitulate the phenotypic alterations seen in HD mice (5, 36, 37). HD mice are also noted to have 279 markedly increased frequency of CD4+ CD8^{low} intermediate thymocytes (38). While this might 280 suggest that class II-restricted thymocytes are arrested at this stage, ThPOK-deficient mice, 281 including HD and knockout models, are reported to have MHC II-restricted CD8+ cells in both

the thymus and spleen, suggesting that in the absence of functional ThPOK, MHC II-restricted thymocytes are reprogrammed to become CD8+ cells. This is supported by *in vitro* studies that show ThPOK-deficient CD4+ CD8^{low} thymocytes can differentiate into CD8+ cells (1, 34). This raises the question of whether all of the patient's CD8+ cells are exclusively MHC I-restricted, or if the subset includes an MHC II-restricted component, an aspect that warrants further investigation.

288 Our study reveals significant differences in the clustering of T cells between the patient 289 and HCs. While the patient's T cells were predominantly naïve CD8+ cells, they did not align with 290 the naïve CD8+ T cell clusters of HCs. This observation implies that the patient's naïve CD8+ T 291 cells possess unique characteristics or alterations that distinguish them from their healthy 292 counterparts. Several factors could contribute to this unique clustering. Differences in TCR 293 repertoires or altered signaling pathways in comparison to HC counterparts could all play a role in 294 the distinct T cell profile of the patient. The patient's immune environment might also influence T 295 cell behavior and clustering. The altered clustering of naïve CD8+ T cells might also reflect 296 changes in their activation potential, survival, or differentiation capacity. Further investigation is 297 required to elucidate the specific factors driving the distinct clustering of the patient's T cells.

In the context of CD4+ T cell biology, our findings complement the established literature by demonstrating that ThPOK not only orchestrates the development of CD4+ T cells in the thymus, but it also regulates the differentiation of several CD4+ T helper cell subsets and the activation and memory potential of both CD4+ and CD8+ T cells in the periphery (*36, 39, 40*). Notably, ThPOK plays a pivotal role in promoting Th2 cell differentiation while concurrently preventing the aberrant trans-differentiation of Th1/Th2 cells into cytotoxic T cell phenotypes (*36, 39*). Our data present an unexpected finding regarding Th2 cells. Contrary to existing reports that

305 show the role of ThPOK in promoting Th2 cells (36, 39), the patient exhibited an increased Th2 306 response, with a significant enhancement in effector cytokine production (IL-4, IL-5, and IL-13) 307 upon PMA/Ionomycin stimulation, suggesting an unanticipated role of ThPOK in modulating Th2 308 cell effector functions in humans. Our findings reveal an intriguing association between the 309 observed increase in Th2 cell responsiveness and the patient's severe atopic manifestations, which 310 encompass early-onset and severe allergic conditions. While our data indicate a distinct Th2 cell 311 hyperresponsiveness mediated by the variant, it remains unclear whether the enhanced Th2 312 responses are T cell intrinsic or influenced by other factors. It is possible that impaired regulatory 313 T cell (Treg) differentiation or function, or altered basophil differentiation or function, may 314 contribute to this phenotype. Additionally, assuming a T cell-intrinsic effect, the increased Th2 315 responses could stem from a loss of normal ThPOK function or the gain of new functions by the 316 variant protein in the allergic inflammatory pathway.

317 ThPOK is also recognized to be important for CD4+ T cell activation, in particular 318 preserving transcriptomic integrity and memory potential. In line with this, we observed a marked 319 deficiency in the upregulation of genes essential for TCR-stimulated activation in naïve CD4+ T 320 cells from the patient compared to HCs, highlighting a significant deficit in proliferative signaling pathways, such as the MYC pathway. The introduction of ThPOK^{WT} into T cells activated by TCR 321 322 led to a notable upregulation of pathways critical for proliferation and effector functions, which 323 were noticeably absent in cells transduced with the variant. Similarly, our research builds upon the 324 known impact of ThPOK deficiency on clonal proliferation and effector molecule production in 325 CD8+ T cells. ThPOK deficiency is shown to markedly impair the clonal proliferation and the 326 production of CD8+ effector molecules, such as IL-2 and granzyme B, within long-lived CD8+ T 327 memory (Tm) cells upon antigenic rechallenge (41). We identified a pronounced impairment in

328 the activation of naïve CD8+ T cells in the patient, evidenced by a significant reduction in the 329 upregulation of genes following TCR stimulation. This was particularly notable in the 330 downregulation of effector pathways, such as those mediated by interferons, which are crucial for 331 the functionality of CD8+ T cells. These findings suggest a direct link between ThPOK function 332 and the activation of mature single-positive T cells. Our results thus provide an understanding of 333 ThPOK's role, not only in the differentiation and development of T cell subsets but also in their 334 activation and functional response, thereby underscoring the complex regulatory mechanisms 335 orchestrated by ThPOK in T cell immunobiology.

336 Beyond challenging the existing paradigm of ThPOK's role in immunity, our study 337 significantly advances the understanding of ThPOK's function in human biology both 338 mechanistically and clinically. Through transcriptomic analysis of transduced primary pulmonary 339 fibroblasts, we uncovered substantial differences in pathway regulation between HC pulmonary fibroblasts expressing ThPOK^{WT} and those expressing the variant. Notably, we observed an 340 341 upregulation in the epithelial-mesenchymal transition pathway, which is particularly relevant due 342 to its association with fibrotic conditions. In addition, overexpression of ThPOK^{K360N} led to an 343 exacerbated fibrotic gene signature, indicative of ThPOK's involvement in regulating fibrotic 344 processes beyond its involvement in the immune system. This was further evidenced by 345 experiments with patient-derived pulmonary fibroblasts, where overexpression of ThPOK^{WT} 346 reversed the fibrotic gene signature, pointing to ThPOK's therapeutic potential in mitigating 347 fibrotic diseases. Thus, our study suggests that genetic changes within ThPOK could have 348 substantial consequences on the gene expression landscape in pulmonary fibroblasts, offering new 349 insights into lung cell biology. Moreover, our exploration of FDA-approved pulmonary fibrosis 350 drugs on patient-derived fibroblasts revealed that pirfenidone significantly reduced the expression

351 of ACTA2, a marker of myofibroblasts and fibrosis, under both steady state and TGF- β -induced 352 fibrotic conditions. The demonstration of pirfenidone's ability to modulate the fibrotic gene 353 signature in patient-derived fibroblasts is particularly promising as it suggests a possible 354 therapeutic approach in managing the fibrotic aspects of diseases associated with ThPOK 355 dysfunction. This finding not only emphasizes the value of targeted therapies in complex genetic 356 diseases but also offers new insights into idiopathic pulmonary fibrosis and other fibrotic lung 357 conditions. Additionally, echogenicity and functional abnormalities have been noted in the 358 patient's liver and kidneys, although these have not been definitively characterized as fibrosis. 359 Given this newly characterized involvement of ThPOK in fibroblast regulation, it prompts 360 speculation about the potential presence of fibrosis in other organs related to this variant. However, 361 the exploration of such a hypothesis is constrained by the ethical and clinical limitations on 362 obtaining biopsies without a clear medical indication from the patient.

363 In conclusion, here we describe a novel human disease associated with a multimorphic 364 damaging variant in ThPOK, establishing its causative link to the patient's clinical profile through 365 complementary experimental approaches. This study not only broadens the scope of ThPOK's 366 known functions in immune regulation but also reveals its tissue-dependent dual regulatory nature, 367 impacting both immune cells and fibroblasts. While our findings offer significant insights, they 368 are derived from a single patient, the only identified case to date, highlighting a limitation and the 369 need for further discovery of similar cases to expand the disease phenotype. Our research opens 370 avenues for further research which includes assessing the impact of ThPOK variants across 371 different tissues and their potential role in non-immune pathologies and a longitudinal study to 372 track the patient's disease progression. Moreover, further investigation into ThPOK's interactions 373 within the immune system, particularly its role in the skewed Th2 immune response, is essential.

- 374 These future directions promise to deepen our understanding of ThPOK's multifaceted role in
- 375 human health and disease, paving the way for improved clinical management and therapeutic
- 376 strategies for patients with ThPOK variant-associated conditions.

377 MATERIALS AND METHODS

378

379 Study design

380 The patient with a previously uncharacterized disease was identified after presenting to the 381 immunology clinic. Trio whole-genome sequencing identified a *de novo* heterozygous variant in 382 ZBTB7B that results in a missense change in the DNA-binding domain of ThPOK. We uncovered 383 the altered DNA binding specificity and transcriptional activity of the variant by multiple 384 approaches, including electrophoretic mobility shift assay (EMSA), high-throughput systematic 385 evolution of ligands by exponential enrichment (HT-SELEX), luciferase assay, and chromatin 386 immunoprecipitation followed by sequencing (ChIP-seq). We performed extensive phenotyping 387 of the patient's peripheral blood cells by single-cell RNA sequencing and conventional flow 388 cytometry to reveal the abnormalities in T cell development, function and activation. To assess the 389 mechanisms underlying the fibroinflammatory changes seen in the patient lung, we employed an 390 *in vitro* system, utilizing lentiviral transduction to introduce both the wild-type (WT) and variant 391 genes into primary pulmonary fibroblasts derived from healthy controls (HCs) and the patient. We 392 also did treatment-testing using two Food and Drug Administration (FDA)-approved antifibrotic 393 agents, one of which successfully reversed the fibrotic gene signature in patient primary pulmonary 394 fibroblasts in an in vitro model of fibrosis.

395

Study approval

The study participant and his parents/guardians and sibling provided written informed consent.
Research study protocols were approved by the University of British Columbia Clinical Research
Ethics Board (H15-00641).

400

401 Genomic analysis

402 Genomic DNA from the patient and parents were sequenced with paired-end reads on the Ilumina

403 platform by GeneDx. See supplementary methods for more details.

404

405 Histopathology

406 A wedge biopsy was obtained from the edge of right upper lobe of the lung in a surgical open
407 biopsy procedure. The immunohistochemistry stainings of the lung tissue were performed in BC

408 Children's Hospital Pathology Laboratory with clinically validated antibodies and protocols.

409

410 Immunoblotting

411 Protein detection was carried out using standard immunoblotting techniques. Details are further 412 elaborated in the supplemental methods. Briefly, HEK293 cells were cultured, transfected with 413 relevant plasmids, lysed, and proteins were extracted. The proteins were separated by SDS-PAGE, 414 transferred to membranes, and probed with anti-ThPOK (D9V5T) Rabbit mAb (Cell Signalling 415 Technology, 1:1000), anti-Myc-Tag (9B11) Mouse mAb (Sigma Aldrich, 1:1000), and anti-β-416 Actin (8H10D10) Mouse mAb (Cell Signalling Technology, 1:20,000). Detection was performed 417 using the Odyssey DLx Near-Infrared Fluorescence Imaging System.

418

419 Luciferase reporter assay

A 1406 bp region of the promoter sequence of human *SOCS* (chr16:11,255,899-11,257,304 on
GRCh38/hg38) was cloned into pGL4.20 [luc2/Puro] (Promega) firefly luciferase reporter
plasmid. Detailed methods are provided in the supplemental section. Briefly, HEK293 cells were

423 seeded in 24-well plates and incubated for 24 hours before transfection with EV, WT, or p.K360N 424 variant plasmids, either individually (250 ng each) or in combination to model heterozygosity with 425 varying ratios of WT to p.K360N (total 250 ng). Each well also received 250 ng of SOCS1-426 luciferase reporter and 10 ng PGL4.74 renilla luciferase control plasmid. Transfections were 427 performed using Lipofectamine[™] 3000. After 24 hours, cell lysates were prepared, and luciferase 428 activity was measured using the Dual-Glo Luciferase Assay Kit (Promega) and a plate reader. In 429 the analysis, firefly luciferase activity was normalized to renilla luciferase to account for 430 transfection efficiency. This normalized activity was then divided by the value from the EV 431 condition, providing a relative measure against the EV baseline.

432

433 Electrophoretic mobility shift assay (EMSA)

434 Preparation of whole cell lysates was performed as previously described in the immunoblotting 435 section above. A section of the SOCS1 promoter, containing the WT ThPOK consensus DNA-436 binding sequence along with two variant sequences identified by HT-SELEX as preferentially 437 bound by variant ThPOK, were used to design the double stranded oligonucleotide probes used in 438 this assay (see Table S3 for sequences). Supershift assays were performed with 5 µg of whole cell 439 protein lysate incubated on ice for 30 min with either anti-ThPOK (D9V5T) Rabbit mAb (Cell 440 Signalling Technology, 1:1000) or Rabbit IgG Isotype Control (Invitrogen, Thermo Fisher 441 Scientific) and then incubated at room temperature for 20 min with the labelled DNA probes and 442 reagents provided in the Odyssey® EMSA Kit (LI-COR Biosciences) according to the 443 manufacturer's recommendations. Protein-oligonucleotide-antibody mixtures were then subjected 444 to electrophoresis in 5% acrylamide/Bis-acrylamide 29:1 gel in 1x Tris-borate-EDTA (TBE)

445 migration buffer (Thermo Scientific) for 90 min at 70 V at room temperature. Imaging was done
446 using the Odyssey DLx Near-Infrared Fluorescence Imaging System (LI-COR Biosciences).
447

448 High Throughput Systematic Evolution of Ligands by EXponential Enrichment (HT449 SELEX)

450 WT and variant ThPOK (ZBTB7B WT and ZBTB7B K360N) were cloned into an eGFP 451 expression vector pF3A-ResEnz-egfp. The TF samples were expressed by using a TNT SP6 High-452 Yield Wheat Germ Protein Expression System Kit (Promega). HT-SELEX was modified from our 453 previous approach (6) to use Abcam Anti-GFP antibody ab290 immobilized to Protein G Mag 454 Sepharose® Xtra Cytiva 28-9670-70) in the step where the protein–DNA complexes are separated 455 from unbound DNA. The assay similarly used IVT-produced proteins, and the selection reactions 456 were carried out in a buffer of 140 mM KCl, 5 mM NaCl, 1 mMK2HPO4, 2 mM MgSO4, 100 µM 457 EGTA, 1 mM ZnSO4, and 20 mM HEPES-HCl (pH 7). After each of the three selection cycles, 458 the ligands were amplified by PCR and output from all cycles was subjected to Illumina 459 sequencing. Mung Bean Nuclease treatment also was used between each of the selection cycles to 460 reduce the ssDNA background during the ligand selection. Data analysis was performed as 461 previously described (42), where automatic detection of a sequence pattern defining local maxima 462 was followed by semi manual generation of seeds that were then used to construct multinomial-1 463 or multinomial-2 position frequency matrices for the transcription factor target specificity.

464

465 Chromatin Immunoprecipitation Sequencing (ChIP-seq)

466 To establish GFP-tagged ThPOK expressing HEK293 Flp-In-TRex cell lines, parental HEK293
467 Flp-In-TRex cells were transfected with separate expression vectors each carrying the WT or

468 variant ZBTB7B open reading frames (FuGENE® HD Transfection Reagent, Promega) and after 469 48 hours transferred to Hygromycin selection media (0.2 ug/ul). Colonies of each line were pooled 470 and used for further experiments. 24 hours prior to cross linking for chromatin 471 immunoprecipitation, doxycycline (100 ng/ml) was added to cells and GFP expression was 472 confirmed with fluorescent microscopy. Chromatin immunoprecipitation was performed as 473 previously described (43). In brief, cells from 15 cm plates at 100% confluency were cross-linked 474 for 10 min in 1% formaldehyde followed by 10 min of quenching with 2M glycine. After washing 475 the cells with cold PBS, cells were collected and pelleted. Using a three-step lysis process, 476 chromatin was released and then sonicated to produce DNA fragment length range of 200-300 bp 477 using a Bioruptor sonicator (Diagenode). GFP-tagged proteins were immunoprecipitated with a 478 polyclonal anti-GFP antibody (ab290, Abcam) and Dynabeads Protein G (Invitrogen). Crosslinks 479 were reversed at 65°C overnight and bound DNA fragments were purified (QIAquick PCR 480 Purification Kit, Qiagen). ChIP libraries were prepared using NEBNext Ultra II DNA kit. 481 Sequencing was performed with 150n paired end at $2x10^7$ reads per sample. For each variant of 482 ZBTB7B, two biological replicates and two input control samples were sequenced using NovaSeq 483 6000 Illumina sequencer.

In the data processing step, adapter sequences were trimmed from ChIP-seq reads with Cutadapt (v2.1) (https://doi.org/10.14806/ej.17.1.200) and mapped to the human genome (hg38) with Bowtie2 (v2.4.1) (44) using the –very-sensitive option. Reads with a map quality of less than 30 were discarded along with PCR duplicates and reads for which one or both of the paired ends could not be mapped. A single set of control reads was generated using the four-input control ChIP-seq replicates by merging them with SAMTools (v1.9) (45) and subsampling to one quarter of the total reads. MACS2 (v2.2.9.1) (46) was used to call peaks for each of WT and variant

491 ThPOK ChIP-seq replicates using the merged input read set as the control. For each set of peaks,

the top 2000 peaks with the highest enrichment scores were used for downstream analyses.

493 For each WT ThPOK ChIP replicate, we scanned the peak sequences to identify peaks that 494 contained a match to the HT-SELEX WT ThPOK motif using FIMO (v5.5.0) (47) with default 495 settings. Using BEDTools intersect (v2.30.0) (48), we overlapped the motif-containing ChIP peak 496 summits for each replicate with a BED file containing the locations of human gene promoter 497 regions (1000 bp upstream of the transcription start site to 500 bp downstream). To establish a set 498 of high-confidence candidates for direct regulation by WT ThPOK, we took the intersection of 499 genes identified from each replicate. We then performed the same analysis using the variant 500 ThPOK ChIP replicates and the variant ThPOK HT-SELEX motif. We searched for 501 overrepresented pathways in the set of high-confidence ThPOK regulated genes and variant 502 ThPOK regulated genes using the PANTHER statistical overrepresentation test with PANTHER 503 pathways (49). We checked each set in its entirety, each set excluding genes that overlapped with 504 the other set, and the intersection of the two sets. We report all overrepresented PANTHER 505 pathways with a false discovery rate P < 0.05.

506

507 Isolation and culture of primary pulmonary fibroblasts

508 Fresh lung tissue was collected from the patient undergoing open lung biopsy for histopathological 509 evaluation of interstitial lung disease. The tissue was immediately transported to the laboratory in 510 ice-cold Dulbecco's Modified Eagle Medium (Thermo Fisher Scientific) supplemented with 1% 511 penicillin-streptomycin (Thermo Fisher Scientific). We followed an optimized published method 512 for generating a fibroblast-enriched single-cell suspension combining mechanical and enzymatic

513 dissociation. Concentrations for all the reagents used are reported in the original study (50). The

514 processed cells were grown using Fibroblast Growth Medium 2 (PromoCell).

515

516 Lentiviral transduction of primary pulmonary fibroblasts

517 To generate lentivirus vectors, WT, and p.K360N cDNA from the previously described expression 518 plasmids were cloned into a GFP-tagged Lenti vector (cat #PS100071, OriGene) using EcoRI-HF 519 and NotI-HF (New England BioLabs). The sequence-verified lentiviral plasmids were packaged 520 using 3rd generation packaging plasmids and transfected into HEK293T cells using 521 LipofectamineTM 3000 Transfection Reagent (Thermo Fisher Scientific). Viral supernatant was 522 harvested and filtered through a 0.45 µm PES filter (Thermo Scientific Nalgene) and concentrated 523 using an Amicon Ultra-15 100 kDa centrifugal filter (Millipore). The concentrated lentivirus 524 solution was then aliquoted and stored at -80°C until use. To establish patient-derived and healthy 525 control-derived pulmonary fibroblasts that stably express WT and p.K360N, patient and healthy 526 control cells were infected with EV, WT, or p.K360N lentiviral particles and 5ug/ml polybrene 527 (Sigma-Aldrich) through spinfection at 1000 x g for 2 hours at 32°C, cultured, and expanded in 528 Fibroblast Growth Medium 2 (PromoCell) for 3 days before undergoing sorting based on GFP 529 expression using BD FACS Aria (BD Biosciences) cell sorter.

530

531 RNA sequencing

To investigate the global transcriptome of the transduced patient and HC primary pulmonary fibroblasts stably expressing EV, WT, or p.K360N variant, 150,000 GFP+ cells were sorted based on GFP expression using BD FACS Aria (BD Biosciences) cell sorter directly into 500 ul of cold Buffer RLT Plus (Qiagen) supplemented with 2-Mercaptoethanol according to the Qiagen RNeasy

Plus Mini Kit instructions. Following sorting, the volume of Buffer RLT Plus was adjusted so that there was exactly 350 ul of Buffer RLT Plus to 100 ul of sorted sample volume. RNA isolation was done according to the RNeasy Plus Mini Kit instructions (Qiagen). Sequencing was done on rRNA depleted RNA libraries using PE150 Illumina NovaSeq Sequencing, targeting 100M individual reads (50M read pairs/clusters) per sample. Three biological replicates were included for each condition, which were independently transduced, sorted, and sequenced.

542 Sequenced reads were aligned to a reference sequence using Spliced Transcripts Alignment 543 to a Reference aligner. E1 Assembly and expression were estimated using Cufflinks E2 through 544 bioinformatics apps on Illumina BaseSpace. Expression data was normalized to reads between 545 samples using the edgeR package in R (R Foundation). Normalized counts were filtered to remove 546 low counts using the filterByExpr function in edge. Principal component analysis (PCA) was done 547 on log2 (normalized counts+0.25) in R using the PCA function. Differential expression analysis 548 was accomplished using Limma. Differentially expressed genes were defined as those with 549 adjusted p-value less than 0.05.

Pathway analysis was done by first performing Gene set enrichment analysis (GSEA) with 1000 permutations using the Molecular Signatures Database Hallmark module. Signal-to-noise ratio was used for gene ranking and the obtained P-values were further adjusted using the Benjamini-Hochberg method. Pathways with an adjusted P-value <0.05 were considered significant. Leading edge genes from significant pathways between WT and p.K360N-transduced cells were identified. Expression levels of these genes were then determined in each group.

556 Sample level enrichment analyses (SLEA) scores were computed for each significant 557 pathway. Briefly, z-scores were computed for gene sets of interest for each sample. The mean 558 expression levels of significant genes were compared to the expression of 1000 random gene sets

559 of the same size. The difference between observed and expected mean expression was then 560 calculated and represented on heatmaps generated using Morpheus 561 (https://software.broadinstitute.org/morpheus).

562

563 Single cell-RNA sequencing (scRNA-seq)

564 Using single cell RNA-Sequencing (scRNA-seq), whole transcriptome analysis (WTA) was 565 conducted on peripheral blood mononuclear cells (PBMCs) from the patient and three age-566 matched healthy controls. The BD Rhapsody Single Cell platform was used, which included the 567 Rhapsody Enhanced Cartridge Reagent Kit (BD), the BD Rhapsody Cartridge Kit (BD), the 568 Rhapsody cDNA Kit (BD), the Rhapsody WTA Amplification Kit (BD), the Human Single-Cell 569 Multiplexing Kit (BD), used according to manufacturer's recommendations and protocols. Briefly, 570 thawed PBMCs were rested overnight and then stimulated with ImmunoCult[™] Human CD3/CD28 571 T Cell Activator (STEMCELL Technologies) or left untreated for 16 hours. Cells from each donor 572 were then labelled with sample tags and a panel of BD® AbSeq Ab-oligos (BD), washed with 573 stain buffer, and pooled together in cold sample buffer to obtain ~60,000 cells in 620 ul for each 574 of the pooled unstimulated and stimulated samples. Two nanowell cartridges were primed and 575 subsequently loaded with the pooled samples. Libraries for whole transcriptome and AbSeq 576 analysis were prepared by following the BD Rhapsody System (TCR/BCR Full Length, mRNA 577 WTA, BD® AbSeq, and Sample Tag Library Preparation) Protocol. Quality control was 578 performed using Agilent DNA High Sensitivity Kit (Agilent Technologies) and the Agilent 2100 579 Bioanalyzer (Agilent Technologies) on the intermediate and final sequencing libraries, including 580 estimating the concentration of each sample, measuring the average fragment size of the libraries, 581 and following sequencing recommendations. Libraries were diluted to 350-650 picomolar range

per sample and sequenced using Illumina NovaSeq 150bp PE sequencing targeting 8,000M
individual reads (4,000M read-pairs) with PhiX spike-in of 20%.

584 FASTQ files were processed using the BD Rhapsody Targeted Analysis Pipeline and Seven 585 Bridges (www.sevenbridges.com) according to manufacturer's recommendations. The R package 586 Seurat was utilized for all downstream analysis. Scaling and clustering were performed on each 587 pool of samples independently. Dimensionality reduction using PCA was done on the most 588 variable genes, and UMAP was based on the first 20 PCs. Cell identities were annotated manually, 589 or via cell surface antibody sequencing (Ab-seq), to first identify major cell types (T cells, B cells, 590 NK cells and Monocytes) and then defining subtypes (CD4+ T cells, CD8+ T cells, Double 591 Positive T cells, and their subsequent Naïve and Memory subgroups). For differential gene 592 expression analyses, we utilized the Seurat implementation of negative binomial test, assuming an 593 underlying negative binomial distribution in RNA-Seq data while leveraging the UMI counts to 594 remove technical noise.

595

596 Flow cytometry

597 To carry out immunophenotyping and intracellular cytokine detection, PBMCs from the patient 598 and age-matched healthy controls were stimulated with eBioscienceTM Cell Stimulation Cocktail 599 (Invitrogen, Thermo Fisher Scientific) for 5 hours at 37°C. One hour after the start of stimulation, 600 eBioscience[™] Protein Transport Inhibitor Cocktail (Invitrogen, Thermo Fisher Scientific) was 601 added to the stimulated cells. Cells were then stained with a cocktail of antibodies against surface 602 markers for 20 minutes in room temperature and then fixed with Foxp3 Fixation/Permeabilization 603 working solution from the eBioscience Foxp3 Transcription Factor Staining Buffer Set 604 (Invitrogen, Thermo Fisher Scientific) for 20 minutes. The fixed cells were subsequently stained

for 20 minutes with antibodies targeting intracellular cytokines in 1x Permeabilization Buffer
(Invitrogen, Thermo Fisher Scientific). The samples were then washed and analyzed using the BD
FACSymphony flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (BD
Biosciences). The antibody panels used for staining are listed in Table S4.

609

610 Treatment testing and qPCR of primary fibroblasts

611 Primary patient pulmonary fibroblasts were used to evaluate the effects of various treatments. 612 Initially, 5x10⁵ cells were plated in each well of a 6-well plate (Corning) containing Fibroblast 613 Growth Medium 2 (PromoCell). The cells were incubated overnight under standard conditions. 614 Subsequently, they were either left untreated or treated with recombinant human TGF- β 1 (R & D 615 Systems) at a concentration of 5 ng/µl for 24 hours to induce a fibrotic state, a well-established in 616 vitro model of fibrosis as documented in existing literature. Following the TGF-B1 treatment, cells 617 were subjected to treatment with Nintedanib (working concentration of 0.1 μ M) or Pirfenidone 618 (working concentration of 1 mM) for an additional 48 hours. Both drugs were purchased from 619 MedChemExpress. For the groups designated to continue with TGF- β 1 exposure, fresh medium 620 supplemented with TGF- β 1 was added concurrently with the drug treatments. This experimental 621 setup allowed for the assessment of drug efficacy in both the presence and absence of an induced 622 fibrotic environment. Post treatment, total RNA was extracted using a RNeasy Plus Mini Kit 623 (Qiagen) and converted to cDNA using an iScript cDNA synthesis kit (BioRad Laboratories). 624 Transcript abundance was measured using a Universal SYBR Green Super Mix (Bio-Rad) and a 625 7300 Real-Time PCR System (Applied Biosystems). Relative transcript abundance was quantified 626 relative to Actin- β (ACTB) using the 2- $\Delta\Delta$ CT method. Pre-designed qPCR primers were purchased 627 from Integrated DNA Technologies.

628

629 Statistical Analysis

- 630 All data are presented as mean ± standard error of the mean (SEM). Statistical significance was
- 631 evaluated using appropriate methods for each dataset which are detailed in the corresponding
- 632 figure legends or the methods section, with the following annotations used to represent
- 633 significance: p-val < 0.05 (*), p-val < 0.01 (**), p-val < 0.001 (***).

634

635 Supplementary Materials

- 636 Materials and Methods
- 637 Figures S1 to S7
- 638 Tables S1 to S4
- 639 Data file S1

640 **References**

641 642

- D. J. Kappes, Expanding roles for ThPOK in thymic development. *Immunol. Rev.* 238, 182-194 (2010).
- 2. Z.-Y. Cheng, T.-T. He, X.-M. Gao, Y. Zhao, J. Wang, ZBTB Transcription Factors: Key
 Regulators of the Development, Differentiation and Effector Function of T Cells. *Front. Immunol.* 12, (2021).
- K. He, K. Park, D. J. Kappes, The Role of ThPOK in Control of CD4/CD8 Lineage
 Commitment. *Annu. Rev. Immunol.* 28, 295-320 (2010).
- P. Galéra, R.-W. Park, P. Ducy, M.-G. Mattéi, G. Karsenty, c-Krox Binds to Several Sites
 in the Promoter of Both Mouse Type I Collagen Genes. J. Biol. Chem. 271, 21331-21339
 (1996).
- M. A. Luckey, M. Y. Kimura, A. T. Waickman, L. Feigenbaum, A. Singer, J.-H. Park, The
 transcription factor ThPOK suppresses Runx3 and imposes CD4+ lineage fate by inducing
 the SOCS suppressors of cytokine signaling. *Nat. Immunol.* 15, 638-645 (2014).
- 6. A. Jolma, J. Yan, T. Whitington, J. Toivonen, Kazuhiro, P. Rastas, E. Morgunova, M.
 657 Enge, M. Taipale, G. Wei, K. Palin, Juan, R. Vincentelli, Nicholas, Timothy, P. Lemaire,
 658 E. Ukkonen, T. Kivioja, J. Taipale, DNA-Binding Specificities of Human Transcription
 659 Factors. *Cell* 152, 327-339 (2013).
- R. Ren, J. R. Horton, Q. Chen, J. Yang, B. Liu, Y. Huang, R. M. Blumenthal, X. Zhang,
 K. Cheng, Structural basis for transcription factor ZBTB7A recognition of DNA and
 effects of ZBTB7A somatic mutations that occur in human acute myeloid leukemia. *J. Biol. Chem.* 299, 102885 (2023).
- A. C. Carpenter, J. R. Grainger, Y. Xiong, Y. Kanno, H. H. Chu, L. Wang, S. Naik, L. dos
 Santos, L. Wei, M. K. Jenkins, J. J. O'Shea, Y. Belkaid, R. Bosselut, The Transcription
 Factors Thpok and LRF Are Necessary and Partly Redundant for T Helper Cell
 Differentiation. *Immunity* 37, 622-633 (2012).
- 668
 9. L. B. Chopp, V. Gopalan, T. Ciucci, A. Ruchinskas, Z. Rae, M. Lagarde, Y. Gao, C. Li,
 669
 M. Bosticardo, F. Pala, F. Livak, M. C. Kelly, S. Hannenhalli, R. Bosselut, An Integrated
 670
 671 *Immunity* 53, 1182-1201 e1188 (2020).
- W. Xu, T. Carr, K. Ramirez, S. McGregor, M. Sigvardsson, B. L. Kee, E2A transcription
 factors limit expression of Gata3 to facilitate T lymphocyte lineage commitment. *Blood* **121**, 1534-1542 (2013).
- T. Egawa, Runx and ThPOK: A balancing act to regulate thymocyte lineage commitment. *J. Cell. Biochem.* 107, 1037-1045 (2009).
- B. Hu, Z. Wu, T. Nakashima, S. H. Phan, Mesenchymal-Specific Deletion of C/EBPβ
 Suppresses Pulmonary Fibrosis. *Am. J. Pathol.* 180, 2257-2267 (2012).
- X. Liu, S. C. Rowan, J. Liang, C. Yao, G. Huang, N. Deng, T. Xie, D. Wu, Y. Wang, A.
 Burman, T. Parimon, Z. Borok, P. Chen, W. C. Parks, C. M. Hogaboam, S. S. Weigt, J.
 Belperio, B. R. Stripp, P. W. Noble, D. Jiang, Categorization of lung mesenchymal cells in
 development and fibrosis. *iScience* 24, 102551 (2021).
- I4. J. Sun, Y. Guo, T. Chen, T. Jin, L. Ma, L. Ai, J. Guo, Z. Niu, R. Yang, Q. Wang, X. Yu,
 H. Gao, Y. Zhang, W. Su, X. Song, W. Ji, Q. Zhang, M. Huang, X. Fan, Z. Du, H. Liang,

685 Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF. *Cell. Death.*686 *Dis.* 13, (2022).

- I. R. Rock, C. E. Barkauskas, M. J. Cronce, Y. Xue, J. R. Harris, J. Liang, P. W. Noble, B.
 L. M. Hogan, Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *Proc. Natl. Acad. Sci. U.S.A* 108, E1475-E1483 (2011).
- 691 16. H. N. Alsafadi, C. A. Staab-Weijnitz, M. Lehmann, M. Lindner, B. Peschel, M.
 692 Königshoff, D. E. Wagner, An ex vivo model to induce early fibrosis-like changes in
 693 human precision-cut lung slices. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 312, L896-L902
 694 (2017).
- F. Nosrati, J. Grillari, M. Azarnia, M. Nabiuni, R. Moghadasali, L. Karimzadeh, I.
 Lämmermann, The expression of fibrosis-related genes is elevated in doxorubicin-induced
 senescent human dermal fibroblasts, but their secretome does not trigger a paracrine
 fibrotic response in non-senescent cells. *Biogerontology* 24, 293-301 (2023).
- 18. T. Wynn, Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
- R. Peyser, S. MacDonnell, Y. Gao, L. Cheng, Y. Kim, T. Kaplan, Q. Ruan, Y. Wei, M. Ni,
 C. Adler, W. Zhang, K. Devalaraja-Narashimha, J. Grindley, G. Halasz, L. Morton,
 Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell
 Sequencing. Am. J. Respir. Cell Mol. Biol. 61, 74-85 (2019).
- M. Chioccioli, S. Roy, R. Newell, L. Pestano, B. Dickinson, K. Rigby, J. Herazo-Maya, G.
 Jenkins, S. Ian, G. Saini, S. R. Johnson, R. Braybrooke, G. Yu, M. Sauler, F. Ahangari, S.
 Ding, J. Deiuliis, N. Aurelien, R. L. Montgomery, N. Kaminski, A lung targeted miR-29
 mimic as a therapy for pulmonary fibrosis. *eBioMedicine* 85, 104304 (2022).
- J. C. Bonner, Mesenchymal cell survival in airway and interstitial pulmonary fibrosis.
 Fibrogenesis Tissue Repair. 3, 15 (2010).
- Y. Enomoto, H. Katsura, T. Fujimura, A. Ogata, S. Baba, A. Yamaoka, M. Kihara, T. Abe,
 O. Nishimura, M. Kadota, D. Hazama, Y. Tanaka, Y. Maniwa, T. Nagano, M. Morimoto,
 Autocrine TGF-beta-positive feedback in profibrotic AT2-lineage cells plays a crucial role
 in non-inflammatory lung fibrogenesis. *Nat. Commun.* 14, 4956 (2023).
- M. Zou, J. Zou, X. Hu, W. Zheng, M. Zhang, Z. Cheng, Latent Transforming Growth
 Factor-β Binding Protein-2 Regulates Lung Fibroblast-to-Myofibroblast Differentiation in
 Pulmonary Fibrosis via NF-κB Signaling. *Front. Pharmacol.* 12, (2021).
- Y. Enomoto, S. Matsushima, K. Shibata, Y. Aoshima, H. Yagi, S. Meguro, H. Kawasaki,
 I. Kosugi, T. Fujisawa, N. Enomoto, N. Inui, Y. Nakamura, T. Suda, T. Iwashita, LTBP2
 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary
 fibrosis. *Clin. Sci.* 132, 1565-1580 (2018).
- E. Cherubini, S. Mariotta, D. Scozzi, R. Mancini, G. Osman, M. D'Ascanio, P. Bruno, G.
 Cardillo, A. Ricci, BDNF/TrkB axis activation promotes epithelial-mesenchymal
 transition in idiopathic pulmonary fibrosis. *J. Transl. Med.* 15, (2017).
- M. Jia, L. Rosas, M. G. Kapetanaki, T. Tabib, J. Sebrat, T. Cruz, A. Bondonese, A. L.
 Mora, R. Lafyatis, M. Rojas, P. V. Benos, Early events marking lung fibroblast transition to profibrotic state in idiopathic pulmonary fibrosis. *Respir. Res.* 24, (2023).
- S. Zhang, L. Zhang, L. Wang, H. Wang, J. Wu, H. Cai, C. Mo, J. Yang, Machine learning
 identified MDK score has prognostic value for idiopathic pulmonary fibrosis based on
 integrated bulk and single cell expression data. *Front. genet.* 14, (2023).

- T. E. King, W. Z. Bradford, S. Castro-Bernardini, E. A. Fagan, I. Glaspole, M. K.
 Glassberg, E. Gorina, P. M. Hopkins, D. Kardatzke, L. Lancaster, D. J. Lederer, S. D.
 Nathan, C. A. Pereira, S. A. Sahn, R. Sussman, J. J. Swigris, P. W. Noble, A Phase 3 Trial
 of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *N. Engl. J. Med.* **370**, 20832092 (2014).
- S. T. Lehtonen, A. Veijola, H. Karvonen, E. Lappi-Blanco, R. Sormunen, S. Korpela, U.
 Zagai, M. C. Sköld, R. Kaarteenaho, Pirfenidone and nintedanib modulate properties of
 fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. *Respir. Res.* 17, (2016).
- J. Jin, S. Togo, K. Kadoya, M. Tulafu, Y. Namba, M. Iwai, J. Watanabe, K. Nagahama, T.
 Okabe, M. Hidayat, Y. Kodama, H. Kitamura, T. Ogura, N. Kitamura, K. Ikeo, S. Sasaki,
 S. Tominaga, K. Takahashi, Pirfenidone attenuates lung fibrotic fibroblast responses to
 transforming growth factor-β1. *Respir. Res.* 20, (2019).
- A. Aimo, G. Spitaleri, D. Nieri, L. M. Tavanti, C. Meschi, G. Panichella, J. Lupón, F.
 Pistelli, L. Carrozzi, A. Bayes-Genis, M. Emdin, Pirfenidone for Idiopathic Pulmonary
 Fibrosis and Beyond. *Card. Fail. Rev.* 8, (2022).
- J.-L. Casanova, M. E. Conley, S. J. Seligman, L. Abel, L. D. Notarangelo, Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. *J. Exp. Med.*211, 2137-2149 (2014).
- X. He, X. He, V. P. Dave, Y. Zhang, X. Hua, E. Nicolas, W. Xu, B. A. Roe, D. J. Kappes,
 The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage
 commitment. *Nature* 433, 826-833 (2005).
- X. He, K. Park, H. Wang, X. He, Y. Zhang, X. Hua, Y. Li, D. J. Kappes, CD4-CD8 Lineage
 Commitment Is Regulated by a Silencer Element at the ThPOK Transcription-Factor
 Locus. *Immunity* 28, 346-358 (2008).
- 35. G. Sun, X. Liu, P. Mercado, S. R. Jenkinson, M. Kypriotou, L. Feigenbaum, P. Galéra, R.
 Bosselut, The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. *Nat. Immunol.* 6, 373-381 (2005).
- 36. L. Wang, K. F. Wildt, E. Castro, Y. Xiong, L. Feigenbaum, L. Tessarollo, R. Bosselut, The
 Zinc Finger Transcription Factor Zbtb7b Represses CD8-Lineage Gene Expression in
 Peripheral CD4+ T Cells. *Immunity* 29, 876-887 (2008).
- 37. L. Wang, K. F. Wildt, J. Zhu, X. Zhang, L. Feigenbaum, L. Tessarollo, W. E. Paul, B. J.
 Fowlkes, R. Bosselut, Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4+ T cells. *Nat. Immunol.* 9, 1122-1130 (2008).
- 38. V. P. Dave, D. Allman, R. Keefe, R. R. Hardy, D. J. Kappes, HD mice: A novel mouse mutant with a specific defect in the generation of CD4+ T cells. *Proc. Natl. Acad. Sci.* U.S.A 95, 8187-8192 (1998).
- M. S. Vacchio, L. Wang, N. Bouladoux, A. C. Carpenter, Y. Xiong, L. C. Williams, E.
 Wohlfert, K.-D. Song, Y. Belkaid, P. E. Love, R. Bosselut, A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells. *Nat. Immunol.* 15, 947-956 (2014).
- Y. C. Twu, H. S. Teh, The ThPOK transcription factor differentially affects the development and function of self-specific CD8(+) T cells and regulatory CD4(+) T cells. *Immunology* 141, 431-445 (2014).
- R. Setoguchi, I. Taniuchi, M. J. Bevan, ThPOK Derepression Is Required for Robust CD8
 T cell Responses to Viral Infection. *J. Immun.* 183, 4467-4474 (2009).

- K. R. Nitta, A. Jolma, Y. Yin, E. Morgunova, T. Kivioja, J. Akhtar, K. Hens, J. Toivonen,
 B. Deplancke, E. E. Furlong, J. Taipale, Conservation of transcription factor binding
 specificities across 600 million years of bilateria evolution. *Elife* 4, (2015).
- 43. D. Schmidt, M. D. Wilson, C. Spyrou, G. D. Brown, J. Hadfield, D. T. Odom, ChIP-seq:
 Using high-throughput sequencing to discover protein–DNA interactions. *Methods* 48, 240-248 (2009).
- 44. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357-359 (2012).
- P. Danecek, J. K. Bonfield, J. Liddle, J. Marshall, V. Ohan, M. O. Pollard, A. Whitwham,
 T. Keane, S. A. McCarthy, R. M. Davies, H. Li, Twelve years of SAMtools and BCFtools. *GigaScience* 10, (2021).
- Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson, B. E. Bernstein, C. Nusbaum,
 R. M. Myers, M. Brown, W. Li, X. S. Liu, Model-based Analysis of ChIP-Seq (MACS). *Genome Biol.* 9, R137 (2008).
- 789 47. C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: scanning for occurrences of a given motif.
 790 *Bioinformatics* 27, 1017-1018 (2011).
- 48. A. R. Quinlan, I. M. Hall, BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26, 841-842 (2010).
- P. D. Thomas, D. Ebert, A. Muruganujan, T. Mushayahama, L. P. Albou, H. Mi,
 PANTHER: Making genome-scale phylogenetics accessible to all. *Protein Sci.* 31, 8-22 (2022).
- 50. S. Waise, R. Parker, M. Rose-Zerilli, D. Layfield, O. Wood, J. West, C. Ottensmeier, G.
 Thomas, C. Hanley, An Optimized Method to Isolate Human Fibroblasts from Tissue for
 Ex Vivo Analysis. *BIO-PROTOCOL* 9, (2019).

799

800 Acknowledgments:

801 We thank the patient and their family members for their participation in our study. We also 802 acknowledge the BC Children's Hospital BioBank for providing age-matched healthy control

- 803 PBMC samples. Additionally, we thank Dr. Jonathan Bramson's lab at McMaster University,
- 804 Ontario, Canada, for providing the optimized lentivirus transduction protocol.
- 805

806 Funding:

- 807 Canadian Institutes of Health Research PJQ-173584 (SET)
- 808 Genome British Columbia SIP007 (SET)
- 809 Tier 1 Canada Research Chair in Pediatric Precision Health (SET)
- 810 Aubrey J. Tingle Professor of Pediatric Immunology (SET)
- 811 Health Professional-Investigator of the Michael Smith Foundation for Health Research (CMB)
- 812 Providence Healthcare Research Institute Early Career Investigator award (CMB)
- 813 Vanier Canada Graduate Scholarship (MV-S)
- 814 Four Year Doctoral Fellowship (MV-S, SS)
- 815

816 Author contributions:

- 817 Conceptualization: MV-S, MS, CMB, SET
- 818 Wet lab experiments: MV-S, MS, PY, SS, RR, AHWY, MB
- 819 Clinical data acquisition: CMB, SET, MV-S, PY, AFL, JHR, CLY, KJH, RB, MKD
- 820 Methodology: MV-S, MS, LDN, TRH, RB
- 821 Bioinformatic analyses: MS, MV-S, KUL, AJ, MA, PAR
- 822 Visualization: MV-S, MS, LG, KUL
- 823 Funding acquisition: CMB, SET
- 824 Supervision: CMB, SET
- 825 Writing original draft: MV-S, MS
- 826 Writing review & editing: All authors

827 **Competing interests**: The authors declare that they have no conflicts of interest related to this 828 manuscript.

- 829 Data and materials availability: HT-SELEX and ChIP-sequencing data is available from ENA
- and SRA databases under accession: PRJEB75580.



831 832

833 Figure 1. Trio genome sequencing revealed a *de novo* heterozygous missense variant in 834 **ZBTB7B** in a pediatric patient with a multi-system disorder. (A) A summary of patient's 835 clinical features. (B) Chest x-ray showing hyperinflated lungs, coarse reticular shadowing, and 836 interstitial septal thickening. (C) Chest CT (coronal view) showing ground glass opacity and 837 subpleural honeycombing changes. (D) Low-power view lung wedge biopsy (H&E stain). (E) 838 CD20 immunohistochemistry highlights (in brown) the B cell population of the lymphoid 839 aggregates in the interlobular septa. (F) CD3 immunohistochemistry highlights (in brown) the T 840 cell population of the lymphoid aggregates in the interlobular and alveolar septa. (G) Subpleural 841 honeycomb change is evident on trichrome stain, which highlights the interstitial fibrosis in blue. 842 (H) The lung architectural abnormalities are patchy (non-uniform), as demonstrated by relatively 843 normal parenchyma in the top half of this image, and interstitial fibrosis and alveolar widening in 844 the lower half (trichrome stain). The patchy changes can also be appreciated in the low-power 845 photomicrographs. (I) Some alveoli contain aggregates of alveolar macrophages surrounding 846 cholesterol clefts (arrowhead), as well as amorphous eosinophilic material (arrow) (H&E stain). 847 All images have scale bars embedded in the respective panels. (J) Illustration of the ThPOK 848 protein, with four C-terminal zinc fingers responsible for DNA-binding to the consensus sequence 849 Location and the N-terminal protein-binding BTB/POZ domain. of the variant 850 (NM 001256455.2:c.1080A>C, p.Lys325Asn) is shown (red dot). ZF, zinc finger. (K) Family 851 pedigree of the patient. Filled symbols = affected individuals; unfilled symbols = unaffected 852 individuals. WT, wild-type. (L) Sanger sequencing results of all family members indicating heterozygous substitution at position 1080 found only in the proband. 853



854

Figure 2. ThPOK^{K360N} showed altered DNA-binding specificity. (A) Comparative analysis of
ThPOK^{K360N} and ThPOK^{WT} protein expression using immunoblotting in HEK293 cells. Protein
was detected using anti-ThPOK and anti-Myc antibodies. β-actin was assessed as loading control.
Representative blot from three independent experiments. (B-C) Luciferase reporter assay using a

859 region of SOCS1 promoter in HEK293 cells transfected with various combinations and ratios of 860 vectors indicated below the plot. Firefly luciferase activity was normalized to Renilla luciferase to 861 account for transfection efficiency variations, with values further normalized to the empty vector 862 (EV) condition, offering a relative comparison to the EV baseline. Data are presented as mean \pm 863 SEM, derived from three independent biological replicates, each comprising of the average of three 864 technical replicates. For panel B, statistical analysis was conducted using one-way ANOVA for 865 repeated measures, with Sidak's method applied for multiple comparisons correction. For panel C, 866 dotted lines represent the 95% confidence intervals for the Pearson correlation coefficient. (D) EMSA showing in vitro DNA binding of ThPOK^{WT} and ThPOK^{K360N}. Whole cell lysates of 867 868 HEK293 cells transfected with an expression vector encoding each protein were incubated with 869 infrared fluorescent dye labeled SOCS1 probe. Anti-ThPOK antibody generated a supershift of the 870 DNA-protein complexes (red arrow). Representative image from three independent experiments. 871 (E) Competitor EMSA assay using an unlabeled (cold) probe identical to the labelled probe sequence. (F) Position weight matrices (PMW) for ThPOK^{WT} and ThPOK^{K360N}, identified from 872 873 HT-SELEX data, showing the relative frequency of nucleotide occurrence at each position within the binding site. (G) Relative binding affinities of ThPOK^{WT} and ThPOK^{K360N} to all 8-base long 874 875 DNA sequences (8-mers). Each point on the plot represents a unique 8-mer, with Z-scores 876 calculated from the number of occurrences of the 8-mer in bound DNA sequences in the third HT-877 SELEX cycle. The sequence of top 8-mer for each protein variant is shown, as well as marginal 878 distributions of 8-mer Z-scores (top and right side of the scatter plot). (H) EMSA showing in vitro DNA binding of ThPOK^{WT} and ThPOK^{K360N} to variant probes designed using binding sequences 879 revealed by HT-SELEX. (I) Schematic depicting identification of ThPOK^{WT} and ThPOK^{K360N} 880 881 regulated genes, i.e., genes with a high-confidence binding site of the protein variant within its

promoter region. For each protein variant, high confidence binding sites were identified as loci with a PWM hit (using HT-SELEX derived motifs) that overlapped a peak from each ChIP-seq replicate. These loci were mapped to promoter regions 1 kb upstream to 0.5 kb downstream of a transcription start site (TSS) to identify genes that are likely regulated by each protein variant. Numbers in the Venn diagram show the total number of genes regulated by ThPOK^{WT} and ThPOK^{K360N}, 36 of which are shared between both.



888

889	Figure 3. Patients CD4+ T cells exhibit impaired development and Th2 skewing post
890	stimulation. (A) Schematic representation of ThPOK's role in T cell lineage commitment. (B)
891	Clinical flow cytometry of patient's CD3+, CD4+, and CD8+ cells over time compared to pediatric
892	healthy control (normal) range. (C) Absolute eosinophil count and serum IgE levels determined
893	by the clinical laboratory over time. (D) Representative flow cytometry plots illustrating the
894	proportions of CD4+ and CD8+ T cells in the patient compared to age-matched pediatric and adult
895	healthy controls (HCs). HC, healthy control; A-HC, adult healthy control; P-HC, pediatric healthy
896	control. Scatter dot plots summarize results from three independent blood draws for the patient
897	compared to three age-matched pediatric (P-HC) and four adult HCs (A-HC). (E) Representative
898	flow cytometry plots showing the proportions of memory and naive CD4+ T cells in the patient,
899	identified by CCR7 and CD45RA markers, compared to age-matched pediatric and adult HCs.
900	Scatter dot plots summarize results from three independent blood draws for the patient compared
901	to three age-matched pediatric and four adult HCs. (F-G) Representative flow cytometry plots and
902	analysis of Th2 cytokine production (IL-4, IL-5, and IL-13) in memory CD4+ T cells post-
903	PMA/ionomycin stimulation. Scatter dot plots display comparative results. Data are mean \pm SEM;
904	statistical significance assessed by one-way ANOVA, with Dunnett's method applied for multiple
905	comparisons correction.



healthy controls. (A) UMAP analysis of peripheral blood mononuclear cells from the patient and

908 Figure 4. Patient T cells exhibit distinct clustering and gene expression profiles compared to

910 two age-matched healthy controls (HCs). HC, healthy controls; PBMC, peripheral blood

909

- 911 mononuclear cells (B) scRNA-seq/Ab-seq analysis reflecting the proportion of CD4+ single
- 912 positive, CD8+ single positive, double positive (DP) and double negative (DN) T cells in the
- 913 patient and two HCs. (C) UMAP analysis of T cell clustering reveals distinct gene signatures
- 914 between patient T cells and HCs. (D) Volcano plot comparing the differential expression of genes
- 915 between DP cells of the patient in comparison to two age-matched HCs using scRNA-seq. (E-H)
- 916 Transcriptome and Hallmark pathway analysis of post-TCR stimulated naïve CD4+ (in E and F)
- 917 and CD8+ T cells (in G and H) in the patient compared to two age-matched HCs. (I) Pathway

918 analysis of the differentially expressed genes assessed by RNA sequencing in HC T cells

919 transduced with empty vector (EV), wild-type (WT), and p.K360N ThPOK.



920



929 diagram illustrating gene expression variations across all three groups in healthy control primary 930 human pulmonary fibroblasts. Each group includes three biological replicates, with each replicate 931 consisting of independently transduced, sorted, processed, and sequenced samples. (F) Sample 932 Level Enrichment Analysis (SLEA) of transduced healthy control lung fibroblasts (G) Expression 933 of profibrotic genes in transduced healthy control lung fibroblasts (H) Experimental schema 934 showing patient-derived primary pulmonary fibroblasts, transduced with WT ThPOK, p.K360N 935 variant, or EV. (I) Expression of profibrotic genes in transduced patient-derived primary lung 936 fibroblasts (J) Expression of ACTA2, a known profibrotic marker, measured by qPCR to evaluate 937 the effect of pirfenidone and nintedanib on profibrotic gene expression in TGF-B-treated patient-938 derived pulmonary fibroblasts. Data are mean \pm SEM; n=6 experiments; statistical analysis was 939 conducted using one-way ANOVA for repeated measures, with post-hoc comparisons performed 940 using Fisher's LSD test.